Overview of the efficacy, efficacy and price of lung cancer drug Tepotinib Hydrochloride Tablets

In the field of lung cancer treatment, a drug called Tepotinib Hydrochloride Tablets (trade name: Tudekang/TEPMETKO) has gradually entered people's field of vision due to its remarkable efficacy in treating non-small cell lung cancer (NSCLC) patients with MET gene exon 14 skipping mutations. This oral small molecule targeted drug effectively blocks the signaling pathways of tumor cell proliferation and metastasis by precisely inhibiting MET receptor tyrosine kinase, bringing new treatment hope to lung cancer patients.

From the perspective of therapeutic effect, the performance of Tepotinib Hydrochloride Tablets is excellent. Data from patients treated with the drug in the closely watched pivotal Phase 2 clinical trial VISION are encouraging. For both treatment-naïve and treatment-experienced patients, the median duration of response (DOR) reached longer months, 10.8 months and 11.1 months respectively. What is even more striking is that a considerable proportion of patients have remission lasting more than 6 months or even 9 months. Specifically, 67% of newly treated patients and 75% of previously treated patients experienced remission for more than half a year, while 30% of newly treated patients and 50% of previously treated patients experienced relief for more than nine months. These data fully prove the significant advantages of Tepotinib Hydrochloride Tablets in controlling lung cancer and prolonging the lives of patients.

Currently, the price of Tepotinib Hydrochloride Tablets (Tudekan/TEPMETKO) has also become the focus of attention of patients and their families. In the Chinese market, a box of 225mg*60 tablets sells for more than 30,000 yuan. This price is unaffordable for many patients. However, it is worth noting that there are also some more affordable generic versions of the drug on the market. For example, the generic version of tepotinib hydrochloride tablets produced by ASEAN in Laos sells for about more than 9,000 yuan per box for the same specification, while the price of the Lao Lucius version is more affordable, about more than 7,000 yuan per box. The emergence of these generic versions of drugs provides patients with more choices.

Although it is expensive, considering the excellent performance of Tepotinib Hydrochloride Tablets in the treatment ofnon-small cell lung cancer with MET-targeted mutations and its significant improvement in the quality of life of patients, this price is reasonable to a certain extent. At the same time, patients can seek ways to reduce their financial burden by consulting professional doctors and understanding medical insurance policies.

In summary, Tepotinib Hydrochloride Tablets is an effective therapeutic drug for patients with non-small cell lung cancer who are positive for exon 14 skipping mutations of the MET gene. Its advantages in controlling the disease and prolonging survival cannot be ignored. However, its price factor needs to be fully considered by patients when purchasing.

References:https://www.drugs.com/newdrugs/fda-approves-tepmetko-tepotinib-first-only-once-daily-oral-met-inhibitor-patients-metastatic-nsclc-5436.html